Elekta


Taking into account possible challenges due to China's corruption crackdown

14/09/23 -"Despite Q1 exceeding expectations, thanks to healthy top-line growth and margin improvements, our target price resets c.10% lower due to potential headwinds related to the Chinese clampdown on ..."

Pages
61
Language
English
Published on
14/09/23
You may also be interested by these reports :
05/11/25
Demant’s Q3 organic sales slightly exceeded expectations, driven by growth in hearing care and hearing aids, though partially offset by weakness in ...

05/11/25
Fresenius delivered strong Q3 results, driven by broad-based growth across Kabi and Helios, with improving margins despite some challenges. Kabi’s ...

05/11/25
Qiagen reported better-than-expected Q3 results, with healthy growth across segments supporting the top line. Profitability also improved, prompting ...

04/11/25
bioMerieux’s Q3 sales fell short of expectations. Organic sales growth was primarily driven by a robust performance in Industrial Applications. ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO